FIELD: molecular biology, protein engineering, biotechnology. SUBSTANCE: plasmid has promoters providing high constitutive expression of gene encoding the fused protein. Fused protein consists of N-terminal fragment of tumor necrosis α-factor bound through peptide fragment Gly-Gln-Gly-Gly-Ser-Arg with amino acid sequence of human proinsulin. Variant of the fused protein has (Гис-)7-fragment at N-end for removal of tumor necrosis α-factor after enzymatic cleavage of the fused protein. Plasmid variants have genes determining the resistance to antibiotic ampicillin and aminoglycosides: kanamycin, neomycin and G-418 for the best selection. Invention can be used for development of human insulin drugs. EFFECT: increased level of synthesis of fused protein and stability of strain-producer. 5 cl
